What Happened?
Shares of health insurance company Humana (NYSE: HUM) jumped 16.8% in the pre-market session after Robert W. Baird upgraded the company to Outperform from Neutral and raised its price target to $596 from $390, following an operational recovery in federal quality ratings.
The company stated in a press release that 95% of its Medicare Advantage members are enrolled in plans rated 4.0 stars or higher for 2027 by the Centers for Medicare and Medicaid Services, up from 25% in the 2025 cycle. A regulatory filing detailed that 42% of members are in 4.5-star contracts, with Humana's largest contract, H5216, returning to a 4.0-star rating.
In research cited by StreetInsider and Yahoo Finance, Baird analyst Michael Ha raised the price target by $206, pointing to greater confidence that Humana can generate more than $35 in adjusted earnings per share in 2028. Ha highlighted conservative benefit designs, restored Stars performance, and easing medical cost growth as catalysts that allow investors to value the stock on rebounding multi-year earnings power. For Medicare Advantage insurers, reaching four stars is the pivotal valuation lever because it unlocks five percent federal quality bonus payments that fund competitive member benefits and widen underwriting margins.
Is now the time to buy Humana? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Humana’s shares are quite volatile and have had 16 moves greater than 5% over the last year. But moves this big are rare even for Humana and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 14 days ago when the stock gained 8% on the news that Barclays upgraded the stock from Equalweight to Overweight.
Barclays analyst Andrew Mok made the rating change on the health insurer's shares per StreetInsider. An Overweight rating means the analyst expects the stock to perform better than the average stock in the sectors or industries the analyst covers. The previous Equalweight rating signaled expected performance in line with those peers. The upgrade reflects a more positive view of the stock and can draw interest from investors who follow Wall Street recommendations.
Humana is up 63.3% since the beginning of the year, and at $431.94 per share, it has set a new 52-week high. Investors who bought $1,000 worth of Humana’s shares 5 years ago would now be looking at an investment worth $1,041.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
